16 Dez 2022 | Press release
TechnoPhage is proud to announce that the Phase I/IIa Clinical Trial of TP-102, a novel bacteriophage cocktail developed for the treatment of infected diabetic foot ulcers, has been successfully completed. This Clinical Trial was designed to evaluate the safety and...
12 Dez 2022 | Press release
TechnoPhage announced that it has provided TP-102, developed for the treatment of infected diabetic foot ulcers, for two compassionate use cases, which took place in July 2022, in Israel. The product was recently evaluated in the scope of the Phase I/IIa clinical...
23 Set 2022 | Press release
TechnoPhage announced the spin-off of T-Oncology AG, which will focus on the development of Antibody Drug Conjugates (ADCs), based on the proprietary Small Domain Antibodies platform (TechnoBodies), for the treatment of cancer. TechnoBodies technology has been...
8 Ago 2022 | Press release
The continued growth of Technophage from a small biotech into a clinical-stage biopharma has resulted in the company making the Financial Times’ 1000 Fastest Growing Companies in Europe for the in 2022. This rating is co-created by the Financial Times and...
25 Jul 2022 | Press release
Technophage, together with partners LX Bio, VectorB2B and FFUL is pleased to announce the signing of a new PRR Grant Agreement with the Portuguese Government, in the scope of the Mobilizing Agendas for Business Innovation in Portugal. The Bio-Hub consortium aims to...
4 Nov 2021 | Press release
TechnoPhage is proud to announce that the first part of the Phase I/IIa Clinical Trial with TP-102 (REVERSE study) has been completed. The study aims to assess the safety and tolerability of this product in individuals with diabetic foot ulcers. According to the data...
